🚀 VC round data is live in beta, check it out!
bioMérieux Valuation Multiples
Discover revenue and EBITDA valuation multiples for bioMérieux and similar public comparables like Guardant Health, United Imaging, Pro Medicus, Eurofins Scientific and more.
bioMérieux Overview
About bioMérieux
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
Founded
1967
HQ
Employees
14.8K
Website
Financials (LTM)
EV
$13B
bioMérieux Financials
bioMérieux reported last 12-month revenue of $5B and EBITDA of $1B.
In the same LTM period, bioMérieux generated $3B in gross profit, $1B in EBITDA, and $522M in net income.
Revenue (LTM)
bioMérieux P&L
In the most recent fiscal year, bioMérieux reported revenue of $5B and EBITDA of $1B.
bioMérieux expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $522M | XXX | $469M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 10% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
bioMérieux Stock Performance
bioMérieux has current market cap of $13B, and enterprise value of $13B.
Market Cap Evolution
bioMérieux's stock price is $107.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $13B | -1.4% | XXX | XXX | XXX | $3.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialbioMérieux Valuation Multiples
bioMérieux trades at 2.6x EV/Revenue multiple, and 10.4x EV/EBITDA.
EV / Revenue (LTM)
bioMérieux Financial Valuation Multiples
As of April 18, 2026, bioMérieux has market cap of $13B and EV of $13B.
Equity research analysts estimate bioMérieux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
bioMérieux has a P/E ratio of 24.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 10.4x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBIT | 17.2x | XXX | 15.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | 4.6x | XXX | XXX | XXX |
| P/E | 24.3x | XXX | 27.0x | XXX | XXX | XXX |
| EV/FCF | 22.7x | XXX | 22.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified bioMérieux Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
bioMérieux Margins & Growth Rates
bioMérieux's revenue in the last 12 month grew by 5%.
bioMérieux's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
bioMérieux's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
bioMérieux's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
bioMérieux Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
bioMérieux Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| bioMérieux | XXX | XXX | XXX | XXX | XXX | XXX |
| Guardant Health | XXX | XXX | XXX | XXX | XXX | XXX |
| United Imaging | XXX | XXX | XXX | XXX | XXX | XXX |
| Pro Medicus | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurofins Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Max Healthcare Institute | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
bioMérieux M&A Activity
bioMérieux acquired XXX companies to date.
Last acquisition by bioMérieux was on XXXXXXXX, XXXXX. bioMérieux acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by bioMérieux
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialbioMérieux Investment Activity
bioMérieux invested in XXX companies to date.
bioMérieux made its latest investment on XXXXXXXX, XXXXX. bioMérieux invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by bioMérieux
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout bioMérieux
| When was bioMérieux founded? | bioMérieux was founded in 1967. |
| Where is bioMérieux headquartered? | bioMérieux is headquartered in France. |
| How many employees does bioMérieux have? | As of today, bioMérieux has over 14K employees. |
| Who is the CEO of bioMérieux? | bioMérieux's CEO is Alexandre Merieux. |
| Is bioMérieux publicly listed? | Yes, bioMérieux is a public company listed on Euronext Paris. |
| What is the stock symbol of bioMérieux? | bioMérieux trades under BIM ticker. |
| When did bioMérieux go public? | bioMérieux went public in 2004. |
| Who are competitors of bioMérieux? | bioMérieux main competitors are Guardant Health, United Imaging, Pro Medicus, Eurofins Scientific. |
| What is the current market cap of bioMérieux? | bioMérieux's current market cap is $13B. |
| What is the current revenue of bioMérieux? | bioMérieux's last 12 months revenue is $5B. |
| What is the current revenue growth of bioMérieux? | bioMérieux revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of bioMérieux? | Current revenue multiple of bioMérieux is 2.6x. |
| Is bioMérieux profitable? | Yes, bioMérieux is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of bioMérieux? | bioMérieux's last 12 months EBITDA is $1B. |
| What is bioMérieux's EBITDA margin? | bioMérieux's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of bioMérieux? | Current EBITDA multiple of bioMérieux is 10.4x. |
| What is the current FCF of bioMérieux? | bioMérieux's last 12 months FCF is $551M. |
| What is bioMérieux's FCF margin? | bioMérieux's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of bioMérieux? | Current FCF multiple of bioMérieux is 22.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.